Amring Pharmaceuticals Boosts Ophthalmology Portfolio with Visant Medical Acquisition

Amring Pharmaceuticals

BERWYN, PA — Amring Pharmaceuticals Inc., a subsidiary of Nordic Group B.V., recently completed the acquisition of Visant Medical, Inc., a leading innovator in Dry Eye Disease (DED) medical technology. This strategic acquisition is set to expand Nordic Pharma’s impact in the global ophthalmology market, starting with the U.S. launch of LACRIFILL, Visant’s FDA-cleared treatment for DED.

LACRIFILL is a hyaluronic acid derivative canalicular occlusive device designed to temporarily block tear drainage by occluding the canalicular system. The device offers a novel approach to treating DED, a condition that affects over 16 million people in the U.S.

“We’re ecstatic Visant Medical selected Nordic Pharma as their partner,” said Philip Gioia, President of the U.S. team that will launch LACRIFILL under the Nordic Pharma brand. “LACRIFILL represents an innovative and elegant form factor to occlude that should become the gold standard for preoperative patient care for those with DED.”

The acquisition of Visant aligns with Nordic Pharma’s focus on ophthalmology and marks the second branded medical device it will introduce in the U.S. Following the anticipated 2024 U.S. launch of LACRIFILL, Nordic Pharma plans to seek regulatory approval to make the product available globally.

“LACRIFILL is set to play a useful role in treating patients with the signs and symptoms of dry eye, especially prior to refractive corneal or cataract surgery,” said Richard Lindstrom, MD, Founder and Attending Surgeon Emeritus at Minnesota Eye Consultants.

Paul Karpecki, OD, Associate Professor, University of Pikeville, Kentucky College of Optometry; Kentucky Eye Institute, noted the unique benefits of LACRIFILL’s hyaluronic acid formulation. “The properties of the hyaluronic acid in a canalicular filler offer unique comfort and effectiveness in managing dry eye symptoms,” he said.

READ:  AscellaHealth Named Among Fastest Growing Companies by The Financial Times for Third Year

The acquisition represents a significant milestone for Amring Pharmaceuticals, boosting its portfolio and positioning it as a key player in the ophthalmology market. With LACRIFILL’s FDA 510(k) clearance and established CPT reimbursement code, patients and providers alike stand to benefit from this innovative treatment option for DED.

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and Microsoft Start.